A biotech spun out of Oxford University can be aiming to develop a universal flu vaccine — in addition to phase 2 trials could be completed by the end of next year.
The company, Vaccitech, says the vaccine — unlike those currently found on the market — does not target surface antibodies. Instead, This specific works through the center of the virus where there are few components which can change the virus strain.
“This specific should protect people against pandemic strains in addition to of which would likely be hugely valuable to have,” Vaccitech co-founder Adrian Hill told CNBC on Friday.
The company’s approach to the flu can be different through what many vaccine manufacturers have adopted, Hill said, adding of which he hopes any Vaccitech success will make pharmaceutical giants take an interest in addition to get involved.
Vaccitech’s strategy has not been tested to work against the flu before, nevertheless Hill said his company has started out trials involving thousands of people.
The tests mark once of which a universal flu vaccine has progressed beyond phase 1 clinical testing in addition to Vaccitech aims to complete phase 2B testing by the end of next year, he said.